Search

Your search keyword '"Terashima, Kotaro"' showing total 14 results
Start Over Author "Terashima, Kotaro" Publication Year Range Last 10 years
14 results on '"Terashima, Kotaro"'

3. Supplementary Figure S2 from Decreased Expression of Fructose-1,6-bisphosphatase Associates with Glucose Metabolism and Tumor Progression in Hepatocellular Carcinoma

Author

Hirata, Hidenari, primary, Sugimachi, Keishi, primary, Komatsu, Hisateru, primary, Ueda, Masami, primary, Masuda, Takaaki, primary, Uchi, Ryutaro, primary, Sakimura, Shotaro, primary, Nambara, Sho, primary, Saito, Tomoko, primary, Shinden, Yoshiaki, primary, Iguchi, Tomohiro, primary, Eguchi, Hidetoshi, primary, Ito, Shuhei, primary, Terashima, Kotaro, primary, Sakamoto, Katsumi, primary, Hirakawa, Masakazu, primary, Honda, Hiroshi, primary, and Mimori, Koshi, primary

Published
2023
Full Text
View/download PDF

4. Supplementary Table S1 from Decreased Expression of Fructose-1,6-bisphosphatase Associates with Glucose Metabolism and Tumor Progression in Hepatocellular Carcinoma

Author

Hirata, Hidenari, primary, Sugimachi, Keishi, primary, Komatsu, Hisateru, primary, Ueda, Masami, primary, Masuda, Takaaki, primary, Uchi, Ryutaro, primary, Sakimura, Shotaro, primary, Nambara, Sho, primary, Saito, Tomoko, primary, Shinden, Yoshiaki, primary, Iguchi, Tomohiro, primary, Eguchi, Hidetoshi, primary, Ito, Shuhei, primary, Terashima, Kotaro, primary, Sakamoto, Katsumi, primary, Hirakawa, Masakazu, primary, Honda, Hiroshi, primary, and Mimori, Koshi, primary

Published
2023
Full Text
View/download PDF

5. Supplementary Materials and Methods, Legends for Supplementary Figures from Decreased Expression of Fructose-1,6-bisphosphatase Associates with Glucose Metabolism and Tumor Progression in Hepatocellular Carcinoma

Author

Hirata, Hidenari, primary, Sugimachi, Keishi, primary, Komatsu, Hisateru, primary, Ueda, Masami, primary, Masuda, Takaaki, primary, Uchi, Ryutaro, primary, Sakimura, Shotaro, primary, Nambara, Sho, primary, Saito, Tomoko, primary, Shinden, Yoshiaki, primary, Iguchi, Tomohiro, primary, Eguchi, Hidetoshi, primary, Ito, Shuhei, primary, Terashima, Kotaro, primary, Sakamoto, Katsumi, primary, Hirakawa, Masakazu, primary, Honda, Hiroshi, primary, and Mimori, Koshi, primary

Published
2023
Full Text
View/download PDF

6. Data from Decreased Expression of Fructose-1,6-bisphosphatase Associates with Glucose Metabolism and Tumor Progression in Hepatocellular Carcinoma

Author

Hirata, Hidenari, primary, Sugimachi, Keishi, primary, Komatsu, Hisateru, primary, Ueda, Masami, primary, Masuda, Takaaki, primary, Uchi, Ryutaro, primary, Sakimura, Shotaro, primary, Nambara, Sho, primary, Saito, Tomoko, primary, Shinden, Yoshiaki, primary, Iguchi, Tomohiro, primary, Eguchi, Hidetoshi, primary, Ito, Shuhei, primary, Terashima, Kotaro, primary, Sakamoto, Katsumi, primary, Hirakawa, Masakazu, primary, Honda, Hiroshi, primary, and Mimori, Koshi, primary

Published
2023
Full Text
View/download PDF

8. Carbon-Ion Radiation Therapy for Pelvic Recurrence of Rectal Cancer

Author

Yamada, Shigeru, Kamada, Tadashi, K, Ebner Daniel, Shinoto, Makoto, Terashima, Kotaro, Isozaki, Yuka, Yasuda, Shigeo, Makishima, Hirokazu, Tsuji, Hiroshi, Tsujii, Hirohiko, Isozaki, Tetsuro, Endo, Satoshi, Takahashi, Keiichi, Sekimoto, Mitsugu, Saito, Norio, and Matsubara, Hisahiro

Subjects
body regions
Abstract

Investigation of the treatment potential of carbon-ion radiation therapy in pelvic recurrence of rectal cancer.

Published
2016

9. Carbon Ion Radiation Therapy With Concurrent Gemcitabine for Patients With Locally Advanced Pancreatic Cancer

Author

Shinoto, Makoto, Yamada, Shigeru, Terashima, Kotaro, Yasuda, Shigeo, Shioyama, Yoshiyuki, Honda, Hiroshi, Kamada, Tadashi, Tsujii, Hirohiko, and Saisho, Hiromitsu

Abstract

To determine, in the setting of locally advanced pancreatic cancer, the maximum tolerated dose of carbon ion radiation therapy (C-ion RT) and gemcitabine dose delivered concurrently and to estimate local effect and survival.

Published
2015

10. Abstract 4411: Loss of fructose-1,6-bisphosphatase expression induces altering glucose metabolism and tumor progression in hepatocellular carcinoma

Author

Wakiyama, Hiroaki, primary, Hirata, Hidenari, additional, Sugimachi, Keishi, additional, Masuda, Takaaki, additional, Hayashi, Naoki, additional, Kuroda, Yohsuke, additional, Ito, Shuhei, additional, Eguchi, Hidetoshi, additional, Terashima, Kotaro, additional, Sakamoto, Katsumi, additional, Hirakawa, Masakazu, additional, Honda, Hiroshi, additional, and Mimori, Koshi, additional

Published
2017
Full Text
View/download PDF

11. Decreased Expression of Fructose-1,6-bisphosphatase Associates with Glucose Metabolism and Tumor Progression in Hepatocellular Carcinoma

Author

Hirata, Hidenari, primary, Sugimachi, Keishi, additional, Komatsu, Hisateru, additional, Ueda, Masami, additional, Masuda, Takaaki, additional, Uchi, Ryutaro, additional, Sakimura, Shotaro, additional, Nambara, Sho, additional, Saito, Tomoko, additional, Shinden, Yoshiaki, additional, Iguchi, Tomohiro, additional, Eguchi, Hidetoshi, additional, Ito, Shuhei, additional, Terashima, Kotaro, additional, Sakamoto, Katsumi, additional, Hirakawa, Masakazu, additional, Honda, Hiroshi, additional, and Mimori, Koshi, additional

Published
2016
Full Text
View/download PDF

12. Carbon Ion Radiation Therapy With Concurrent Gemcitabine for Patients With Locally Advanced Pancreatic Cancer

Author

Shinoto, Makoto, primary, Yamada, Shigeru, additional, Terashima, Kotaro, additional, Yasuda, Shigeo, additional, Shioyama, Yoshiyuki, additional, Honda, Hiroshi, additional, Kamada, Tadashi, additional, Tsujii, Hirohiko, additional, Saisho, Hiromitsu, additional, Asano, Takehide, additional, Yamaguchi, Taketo, additional, Amano, Hodaka, additional, Ishihara, Takeshi, additional, Otsuka, Masayuki, additional, Matsuda, Masamichi, additional, Kainuma, Osamu, additional, Funakoshi, Akihiro, additional, Furuse, Junji, additional, Nakagori, Toshio, additional, Okusaka, Takuji, additional, Ishii, Hiroshi, additional, Nagakawa, Tatsuya, additional, Takahashi, Shinichiro, additional, Hishinuma, Shoichi, additional, Nakamura, Masafumi, additional, Saito, Hirofumi, additional, Ohara, Kiyoshi, additional, Ohkawa, Shinichi, additional, and Hiraoka, Masahiro, additional

Published
2016
Full Text
View/download PDF

13. Prognostic Significance of a Minute Amount of Ascites During Chemoradiotherapy for Locally Advanced Pancreatic Cancer.

Author

Shinoto M, Nakamura K, Shioyama Y, Sasaki T, Nishie A, Asayama Y, Ohga S, Yoshitake T, Terashima K, Asai K, Matsumoto K, and Honda H

Subjects
Adult, Aged, Aged, 80 and over, Antineoplastic Agents therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Chemoradiotherapy adverse effects, Cisplatin therapeutic use, Deoxycytidine analogs & derivatives, Deoxycytidine therapeutic use, Drug Combinations, Etoposide therapeutic use, Female, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Oxonic Acid therapeutic use, Pancreatic Neoplasms blood, Pancreatic Neoplasms diagnostic imaging, Prognosis, Tegafur therapeutic use, Tomography, X-Ray Computed, Gemcitabine, Ascites, CA-19-9 Antigen blood, Pancreatic Neoplasms therapy
Abstract

Aim: The aim of this study was to investigate the clinical factors for predicting overall survival (OS) and the significance of a minute amount of ascites on computed tomography (CT) in patients with locally advanced pancreatic cancer (LAPC) treated with chemoradiotherapy (CRT)., Patients and Methods: Between 2003 and 2011, 48 consecutive patients with LAPC were treated with CRT. Various clinical factors, including ascites, were evaluated for correlation with OS. A subset analysis of 16 patients with a minute amount of ascites was also performed., Results: The median survival duration and the 1-year OS rates were 11.5 months and 50%, respectively. A minute amount of ascites on CT and elevated carbohydrate antigen 19-9 (CA19-9) level were significantly associated with poorer OS. In 16 patients with ascites, the amount of ascites increased in the course of the disease, and these were considered to be cancerous clinically, regardless of the amount., Conclusion: A minute amount of ascites and CA19-9 were important prognostic factors in CRT. Any amount of ascites was considered an early indicator of peritoneal carcinomatosis in LAPC., (Copyright© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.)

Published
2016

14. Treatment Outcome of Radiotherapy for Localized Primary Ocular Adnexal MALT Lymphoma--Prognostic Effect of the AJCC Tumor-Node-Metastasis Clinical Staging System.

Author

Ohga S, Nakamura K, Shioyama Y, Sasaki T, Yamaguchi T, Yoshitake T, Terashima K, Asai K, Matsumoto K, and Honda H

Subjects
Adnexal Diseases pathology, Adult, Aged, Aged, 80 and over, Disease-Free Survival, Eye Neoplasms pathology, Female, Humans, Kaplan-Meier Estimate, Lymphoma, B-Cell, Marginal Zone pathology, Male, Middle Aged, Neoplasm Staging, Radiation Dosage, Treatment Outcome, Adnexal Diseases radiotherapy, Eye Neoplasms radiotherapy, Lymphoma, B-Cell, Marginal Zone radiotherapy, Prognosis
Abstract

Aim: To analyze the treatment outcome of radiotherapy for localized primary ocular adnexal mucosa-associated lymphoid tissue lymphoma (POAML) and evaluate the prognostic effect of the American Joint Committee on Cancer (AJCC) tumor-node-metastasis (TNM) clinical staging system for POAML., Patients and Methods: Seventy-three patients with Ann Arbor stage IE POAML who were treated with radiotherapy alone were analyzed. T-Factor based on the AJCC staging system was T1 in 28, T2 in 33 and T3 in 12 patients., Results: Out of nine patients with relapse, six had distant and three had contralateral ocular adnexal relapse. One patient died of lymphoma progression. The 5-year local control and progression-free survival (PFS) rates were 100% and 81.5%, respectively. T-Factor was not significantly associated with PFS., Conclusion: Radiotherapy achieved excellent local control and survival rates for stage IE POAML. The AJCC TNM clinical staging system was not significantly predictive for PFS of stage IE POAML., (Copyright© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.)

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results